MedTrace Logo

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

NCT01270828 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 806

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)

Conditions

  • Post Herpetic Neuralgia

Interventions

DRUG

Pregabalin

Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks

DRUG

placebo

Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-09-30
Completion
2014-11-30

Countries

  • United States
  • Bulgaria
  • Colombia
  • Croatia
  • Czechia
  • Denmark
  • Germany
  • Hong Kong
  • India
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • Sweden
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270828 on ClinicalTrials.gov